[A22-102] Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2023
Project no.:
A22-102
Commission:
Commission awarded on 29.09.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
adjuvant treatment of adult patients with HER2-positive, early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative)
indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A13-10 | Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A13-28 | Addendum to Commission A13-10 (pertuzumab) | Commission completed |
| A15-34 | Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A16-01 | Pertuzumab - Addendum to Commission A15-34 | Commission completed |
| A18-41 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-76 | Pertuzumab (breast cancer) - Addendum to Commission A18-41 | Commission completed |